Microbot Medical (NASDAQ:MBOT) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Friday.
Separately, Ladenburg Thalmann Financial Services started coverage on shares of Microbot Medical in a research report on Wednesday. They set a “buy” rating and a $1.75 price objective on the stock.
Microbot Medical (NASDAQ:MBOT) traded down $0.04 during trading on Friday, hitting $1.04. 1,212,724 shares of the stock traded hands, compared to its average volume of 832,689. The stock has a market cap of $40.15, a PE ratio of -1.51 and a beta of -0.39. Microbot Medical has a 12-month low of $1.00 and a 12-month high of $9.94.
A hedge fund recently raised its stake in Microbot Medical stock. Vanguard Group Inc. grew its stake in shares of Microbot Medical Inc (NASDAQ:MBOT) by 252.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 159,992 shares of the biotechnology company’s stock after buying an additional 114,561 shares during the quarter. Vanguard Group Inc. owned 0.43% of Microbot Medical worth $228,000 at the end of the most recent quarter. Institutional investors and hedge funds own 4.67% of the company’s stock.
Microbot Medical Company Profile
Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.